Embecta (EMBC) Projected to Post Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $256.08 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Tuesday, November 26th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.40 by $0.05. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. The company had revenue of $286.10 million for the quarter, compared to analyst estimates of $276.97 million. During the same period in the prior year, the company earned $0.59 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Performance

NASDAQ:EMBC opened at $17.95 on Tuesday. Embecta has a one year low of $9.93 and a one year high of $21.48. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 13.30, a PEG ratio of 0.97 and a beta of 1.20. The firm’s fifty day moving average is $19.76 and its two-hundred day moving average is $16.47.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 3.34%. The ex-dividend date of this dividend was Friday, December 6th. Embecta’s payout ratio is 44.44%.

Analysts Set New Price Targets

Several research firms have commented on EMBC. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $13.00 to $20.00 in a report on Monday, December 2nd. BTIG Research raised shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.